Comparative protein binding of Taxotere and SID530, a new docetaxel formulation with hydroxypropyl-beta-cyclodextrin, in human plasma in vitro
- Authors
- Kim, T. K.; Yoo, H. H.; Kim, E. J.; Sa, J. H.; Lee, B. -Y.; Park, Jeong Hill
- Issue Date
- Sep-2012
- Publisher
- Govi Verlag Pharmazeutischer Verlag GmbH
- Keywords
- UNBOUND DOCETAXEL; CLINICAL PHARMACOKINETICS; CANCER
- Citation
- Die Pharmazie, v.67, no.9, pp.789 - 791
- Indexed
- SCIE
SCOPUS
- Journal Title
- Die Pharmazie
- Volume
- 67
- Number
- 9
- Start Page
- 789
- End Page
- 791
- URI
- https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/32160
- DOI
- 10.1691/ph.2012.1149
- ISSN
- 0031-7144
- Abstract
- The purpose of this study was to evaluate the plasma-protein binding of docetaxel in two different formulations, Taxotere and SID530, a new docetaxel formulation with hydroxypropyl-beta-cyclodextrin (HP-beta-CD), in human plasma in vitro, using equilibrium dialysis. Unbound docetaxel concentration in the human plasma was determined by LC-MS/MS analysis. SID530 showed a plasma-protein binding profile comparable to that of Taxotere in the clinically relevant concentration range of docetaxel. In both formulations, the unbound fraction of docetaxel increased in a concentration-dependent biphasic manner. The resulting data indicate that the excipient used in SID530, HP-beta-CD, generates similar effects as polysorbate 80 of Taxotere in terms of plasma-protein binding of docetaxel.
- Files in This Item
-
Go to Link
- Appears in
Collections - COLLEGE OF PHARMACY > DEPARTMENT OF PHARMACY > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.